ID

39642

Beschrijving

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial; ODM derived from: https://clinicaltrials.gov/show/NCT01492504

Link

https://clinicaltrials.gov/show/NCT01492504

Trefwoorden

Versies (1)
  1. 07-02-20 07-02-20 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

7 februari 2020

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Hepatitis C NCT01492504

Engels

Eligibility Hepatitis C NCT01492504

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
signed written informed consent
Beschrijving

Informed Consent

Datatype

boolean

Alias
UMLS CUI [1]
C0021430
subjects must have received at least one dose of asunaprevir and/or daclatasvir
Beschrijving

Asunaprevir Dose Quantity | Daclatasvir Dose Quantity

Datatype

boolean

Alias
UMLS CUI [1,1]
C3491974
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C1265611
UMLS CUI [2,1]
C3252090
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C1265611
subjects participating in daclatasvir and/or asunaprevir studies (ie, protocol numbers beginning with ai443, ai444 or ai447) may enroll regardless of virologic response
Beschrijving

Study Subject Participation Status Clinical Trial Daclatasvir | Study Subject Participation Status Clinical Trial Asunaprevir | Enrollment Independent of Virologic Response

Datatype

boolean

Alias
UMLS CUI [1,1]
C2348568
UMLS CUI [1,2]
C0008976
UMLS CUI [1,3]
C3252090
UMLS CUI [2,1]
C2348568
UMLS CUI [2,2]
C0008976
UMLS CUI [2,3]
C3491974
UMLS CUI [3,1]
C1516879
UMLS CUI [3,2]
C0332291
UMLS CUI [3,3]
C4053862
completed the required post-treatment follow-up period in previous study
Beschrijving

Clinical Trial Previous | Follow-up Completed

Datatype

boolean

Alias
UMLS CUI [1,1]
C0008976
UMLS CUI [1,2]
C0205156
UMLS CUI [2,1]
C3274571
UMLS CUI [2,2]
C0205197
must enroll in this study within 6 months of completing previous bms study or within 6 months of protocol availability at the clinical site
Beschrijving

Study Subject Participation Status | Clinical Trial Previous Completed

Datatype

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2,1]
C0008976
UMLS CUI [2,2]
C0205156
UMLS CUI [2,3]
C0205197
men and women, ages 18 and older
Beschrijving

Age

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
subject must not have been treated with any antiviral or immunomodulatory drug for chronic hepatitis c (chc) after completion of the previous study during which asunaprevir and/or daclatasvir were administered
Beschrijving

Antiviral Therapy Chronic Hepatitis C | Immunomodulatory therapy Chronic Hepatitis C

Datatype

boolean

Alias
UMLS CUI [1,1]
C0280274
UMLS CUI [1,2]
C0524910
UMLS CUI [2,1]
C1963758
UMLS CUI [2,2]
C0524910
subject must not be participating in any other trial, excluding non-interventional trials
Beschrijving

Study Subject Participation Status | Clinical Trial | Exception Interventional procedure Absent

Datatype

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0008976
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0184661
UMLS CUI [3,3]
C0332197
prisoners or subjects who are involuntarily incarcerated
Beschrijving

Prisoners | Study Subject incarcerated

Datatype

boolean

Alias
UMLS CUI [1]
C0033167
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0392751
subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
Beschrijving

Study Subject Incarcerated | Psychiatric therapeutic procedure | Treatment Physical illness | Treatment Communicable Disease

Datatype

boolean

Alias
UMLS CUI [1,1]
C0681850
UMLS CUI [1,2]
C0392751
UMLS CUI [2]
C0204523
UMLS CUI [3,1]
C0087111
UMLS CUI [3,2]
C0683323
UMLS CUI [4,1]
C0087111
UMLS CUI [4,2]
C0009450
Terug naar het begin van de pagina

Similar models

Eligibility Hepatitis C NCT01492504

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
signed written informed consent
boolean
C0021430 (UMLS CUI [1])
Asunaprevir Dose Quantity | Daclatasvir Dose Quantity
Item
subjects must have received at least one dose of asunaprevir and/or daclatasvir
boolean
C3491974 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C3252090 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
Study Subject Participation Status Clinical Trial Daclatasvir | Study Subject Participation Status Clinical Trial Asunaprevir | Enrollment Independent of Virologic Response
Item
subjects participating in daclatasvir and/or asunaprevir studies (ie, protocol numbers beginning with ai443, ai444 or ai447) may enroll regardless of virologic response
boolean
C2348568 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
C3252090 (UMLS CUI [1,3])
C2348568 (UMLS CUI [2,1])
C0008976 (UMLS CUI [2,2])
C3491974 (UMLS CUI [2,3])
C1516879 (UMLS CUI [3,1])
C0332291 (UMLS CUI [3,2])
C4053862 (UMLS CUI [3,3])
Clinical Trial Previous | Follow-up Completed
Item
completed the required post-treatment follow-up period in previous study
boolean
C0008976 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C3274571 (UMLS CUI [2,1])
C0205197 (UMLS CUI [2,2])
Study Subject Participation Status | Clinical Trial Previous Completed
Item
must enroll in this study within 6 months of completing previous bms study or within 6 months of protocol availability at the clinical site
boolean
C2348568 (UMLS CUI [1])
C0008976 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
C0205197 (UMLS CUI [2,3])
Age
Item
men and women, ages 18 and older
boolean
C0001779 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Antiviral Therapy Chronic Hepatitis C | Immunomodulatory therapy Chronic Hepatitis C
Item
subject must not have been treated with any antiviral or immunomodulatory drug for chronic hepatitis c (chc) after completion of the previous study during which asunaprevir and/or daclatasvir were administered
boolean
C0280274 (UMLS CUI [1,1])
C0524910 (UMLS CUI [1,2])
C1963758 (UMLS CUI [2,1])
C0524910 (UMLS CUI [2,2])
Study Subject Participation Status | Clinical Trial | Exception Interventional procedure Absent
Item
subject must not be participating in any other trial, excluding non-interventional trials
boolean
C2348568 (UMLS CUI [1])
C0008976 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0184661 (UMLS CUI [3,2])
C0332197 (UMLS CUI [3,3])
Prisoners | Study Subject incarcerated
Item
prisoners or subjects who are involuntarily incarcerated
boolean
C0033167 (UMLS CUI [1])
C0681850 (UMLS CUI [2,1])
C0392751 (UMLS CUI [2,2])
Study Subject Incarcerated | Psychiatric therapeutic procedure | Treatment Physical illness | Treatment Communicable Disease
Item
subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
boolean
C0681850 (UMLS CUI [1,1])
C0392751 (UMLS CUI [1,2])
C0204523 (UMLS CUI [2])
C0087111 (UMLS CUI [3,1])
C0683323 (UMLS CUI [3,2])
C0087111 (UMLS CUI [4,1])
C0009450 (UMLS CUI [4,2])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial